CLAIMS

1. Use of a substance that suppresses an expression of Syndecan-4 (SDC4) in the manufacture of a medicament for treating cancer, wherein the substance that suppresses the expression of SDC4 is
a nucleic acid comprising a nucleotide sequence complementary to a sequence consisting of at least 15 consecutive nucleotides in the region indicated by nucleotide numbers 475 - 606 in the nucleotide sequence shown in SEQ ID NO: 1, or a precursor thereof,
wherein the cancer is a colorectal cancer, pancreatic cancer or mesothelioma, and
wherein the medicament eliminates cancer stem cells in the cancer.

2. The use according to claim 1, wherein the substance that suppresses the expression of SDC4 is a nucleic acid comprising a nucleotide sequence complementary to a sequence consisting of at least 15 consecutive nucleotides in the region indicated by nucleotide numbers 564 - 594 in the nucleotide sequence shown in SEQ ID NO: 1, or a precursor thereof.

3. The use according to claim 1 or 2, wherein the nucleic acid is siRNA.

4. The use according to claim 3, wherein the siRNA comprises a pair of the nucleotide sequences selected from the group consisting of (i) SEQ ID NOs: 3 and 4, (ii) SEQ ID NOs: 5 and 6, and (iii) SEQ ID NOs: 11 and 12.

5. The use according to any one of claims 1 to 4, wherein the medicament is to be used in combination with other antitumor drug.

6. The use according to claim 5, wherein said other antitumor drug is one or more kinds selected from a chemotherapy drug, a Wnt inhibitor and an mTOR inhibitor.